glesatinib + sitravatinib + mocetinostat

A combination regimen consisting of **glesatinib**, **sitravatinib**, and **mocetinostat**—each an investigational **small molecule inhibitor**—has been evaluated in parallel, in combination with immune checkpoint inhibitor nivolumab, for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC). - **Glesatinib** is a multi-targeted tyrosine kinase inhibitor of **MET** and **AXL** receptors, associated with dysregulated signaling in NSCLC. - **Sitravatinib** inhibits a spectrum of receptor tyrosine kinases (RTKs), including **MET, AXL, MERTK, VEGFR family, PDGFR family, KIT, FLT3, Trk family, RET, DDR2, and selected Eph family members**. - **Mocetinostat** is a histone deacetylase (**HDAC**) inhibitor with epigenetic modulating activity. All agents are orally administered small molecules and intended for use with nivolumab (a monoclonal antibody inhibiting PD-1). This combination was tested in Phase 2 trials in NSCLC patients pre-treated with checkpoint inhibitors or platinum-based chemotherapy. Cohorts received each agent separately, not the three-drug combination together[1][3][9]. No identified evidence supports clinical use of the three agents as a single, combined drug product, only as parallel individual combinations with immunotherapy in trial arms.

Brand names

none known; all are investigational drugs

Other names

none known; drug names are standard